|8.03||+0.2300||+2.95%||Vol 450.47K||1Y Perf 9.40%|
|Oct 3rd, 2023 16:00 DELAYED|
|- -||0.12 1.49%|
|Target Price||32.80||Analyst Rating||Strong Buy 1.00|
|Potential %||308.47||Finscreener Ranking||★★★★★ 60.49|
|Insiders Trans % 3/6/12 mo.||-/100/-||Value Ranking||★★★+ 54.41|
|Insiders Value % 3/6/12 mo.||-/100/-89||Growth Ranking||★★★★ 58.50|
|Insiders Shares Cnt. % 3/6/12 mo.||-/100/-82||Income Ranking||— -|
|Price Range Ratio 52W %||43.46||Earnings Rating||Neutral|
|Market Cap||280.92M||Earnings Date||1st Nov 2023|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||1st Nov 2023|
|Estimated EPS Next Report||-0.62|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||527.45K|
|Avg. Monthly Volume||511.59K|
|Avg. Quarterly Volume||596.01K|
EyePoint Pharmaceuticals Inc. (NASDAQ: EYPT) stock closed at 7.8 per share at the end of the most recent trading day (a -2.38% change compared to the prior day closing price) with a volume of 854.61K shares and market capitalization of 280.92M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 84 people. EyePoint Pharmaceuticals Inc. CEO is Nancy Lurker.
The one-year performance of EyePoint Pharmaceuticals Inc. stock is 9.4%, while year-to-date (YTD) performance is 122.86%. EYPT stock has a five-year performance of -79.31%. Its 52-week range is between 2.19 and 15.6263, which gives EYPT stock a 52-week price range ratio of 43.46%
EyePoint Pharmaceuticals Inc. currently has a PE ratio of -1.50, a price-to-book (PB) ratio of 0.81, a price-to-sale (PS) ratio of 3.61, a price to cashflow ratio of 10.50, a PEG ratio of -, a ROA of -43.10%, a ROC of -46.48% and a ROE of -72.80%. The company’s profit margin is -%, its EBITDA margin is -168.90%, and its revenue ttm is $30.87 Million , which makes it $0.91 revenue per share.
Of the last four earnings reports from EyePoint Pharmaceuticals Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.62 for the next earnings report. EyePoint Pharmaceuticals Inc.’s next earnings report date is 01st Nov 2023.
The consensus rating of Wall Street analysts for EyePoint Pharmaceuticals Inc. is Strong Buy (1), with a target price of $32.8, which is +308.47% compared to the current price. The earnings rating for EyePoint Pharmaceuticals Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
EyePoint Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
EyePoint Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 23.61, ATR14 : 0.90, CCI20 : -89.75, Chaikin Money Flow : -0.26, MACD : -0.94, Money Flow Index : 17.63, ROC : -29.09, RSI : 32.96, STOCH (14,3) : 5.47, STOCH RSI : 0.00, UO : 32.62, Williams %R : -94.53), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of EyePoint Pharmaceuticals Inc. in the last 12-months were: ADAMIS ANTHONY P (Option Exercise at a value of $0), Adamis Anthony P. (Sold 0 shares of value $0 ), Dario A. Paggiarino (Sold 0 shares of value $0 ), David Guyer (Option Excercise at a value of $0), David R. Guyer (Option Excercise at a value of $0), David Scott Jones (Option Excercise at a value of $0), Dicicco Wendy (Option Excercise at a value of $0), George O. Elston (Option Excercise at a value of $0), Goran A. Ando (Option Excercise at a value of $0), Jay Duker (Sold 0 shares of value $0 ), Jay S. Duker (Option Excercise at a value of $0), John B. Landis (Option Excercise at a value of $0), Jones David Scott (Sold 0 shares of value $0 ), Landis John (Option Excercise at a value of $0), Liu Ye (Sold 1 shares of value $6 ), Nancy S. Lurker (Option Excercise at a value of $0), Wendy F. DiCicco (Option Excercise at a value of $0)
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.